List of Excipients in Branded Drug SOFOSBUVIR AND VELPATASVIR

« Back to Dashboard

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	ALCOHOL	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	CELLULOSE, MICROCRYSTALLINE	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	COPOVIDONE K25-31	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	CROSCARMELLOSE SODIUM	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	FERRIC OXIDE RED	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	MAGNESIUM STEARATE	2034-07-30
Asegua Therapeutics LLC	SOFOSBUVIR AND VELPATASVIR	velpatasvir and sofosbuvir	72626-2701	POLYETHYLENE GLYCOL 3350	2034-07-30

Last updated: October 18, 2026

Executive summary: Sofosbuvir/velpatasvir is a high-volume fixed-dose combination opportunity for generic manufacturers, public-health suppliers, and excipient vendors. The principal formulation challenge is balancing velpatasvir’s low aqueous solubility and pH sensitivity with tablet manufacturability, chemical stability, rapid dissolution, and low cost. The reference product, Epclusa, uses a conventional immediate-release tablet platform built around copovidone, croscarmellose sodium, lactose monohydrate, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate. The strongest commercial opportunities are bioequivalent generic tablets, pediatric and dysphagia-friendly presentations, regionally optimized excipient systems, and supply programs for licensed manufacturers in lower- and middle-income markets.

Sofosbuvir and Velpatasvir Excipient Strategy and Commercial Opportunities

What is the formulation profile of sofosbuvir/velpatasvir?

Sofosbuvir/velpatasvir is an oral, fixed-dose combination for chronic hepatitis C virus infection. The U.S. reference product, Epclusa, contains 400 mg of sofosbuvir and 100 mg of velpatasvir per tablet. It is approved for adults and certain pediatric patients aged 3 years and older, with or without ribavirin depending on the clinical setting [1].

The formulation is an immediate-release, film-coated tablet. The commercial formulation must deliver two chemically and biopharmaceutically different active pharmaceutical ingredients:

Attribute	Sofosbuvir	Velpatasvir
Drug class	Nucleotide analog NS5B polymerase inhibitor	NS5A inhibitor
Formulation concern	API stability, content uniformity, solid-state control	Low aqueous solubility, pH-dependent dissolution
Dose in Epclusa	400 mg	100 mg
Product format	Fixed-dose immediate-release tablet	Fixed-dose immediate-release tablet
Main development risk	Degradation and blend uniformity	Dissolution, precipitation, and exposure variability

Velpatasvir is the more demanding component from an excipient-design perspective. Its solubility is affected by gastric pH, which explains the clinical interaction with acid-reducing agents. The excipient system must support rapid wetting, dispersion, and dissolution without creating excessive hydrophobicity or tablet hardness.

What excipients are used in Epclusa tablets?

The U.S. prescribing information identifies the following core inactive ingredients for Epclusa tablets:

Excipient	Primary formulation function
Copovidone	Binder and wetting-support polymer
Croscarmellose sodium	Superdisintegrant
Lactose monohydrate	Diluent and compressibility aid
Microcrystalline cellulose	Diluent, dry binder, and tablet-strength contributor
Colloidal silicon dioxide	Glidant and moisture-flow aid
Magnesium stearate	Lubricant
Polyvinyl alcohol	Film-coating polymer
Polyethylene glycol	Film-coating plasticizer
Talc	Anti-tacking and coating aid
Titanium dioxide and colorants	Opacity and product identification

The exact coating colorant system can differ by jurisdiction and manufacturing site. The U.S. label should control any U.S. development or substitution analysis [1].

The reference composition is commercially significant because it relies on widely available, compendial excipients rather than a highly specialized delivery technology. That structure lowers manufacturing complexity and supports multiple generic development paths.

How should excipients be selected for a generic sofosbuvir/velpatasvir tablet?

A generic developer should treat the formulation as a dissolution-sensitive fixed-dose combination, not as a simple proportional replication of a conventional tablet.

Binder and diluent strategy

Copovidone, microcrystalline cellulose, and lactose provide a flexible direct-compression or dry-granulation platform. Copovidone can improve tablet tensile strength and support uniform distribution of the two APIs. Microcrystalline cellulose contributes compactibility and helps maintain tablet integrity at a relatively low tablet weight.

Lactose is commercially attractive because it is inexpensive and widely qualified. Its use requires control of water activity, particle-size distribution, and API-excipient compatibility. Lactose-free alternatives such as mannitol, dibasic calcium phosphate, or additional microcrystalline cellulose may support differentiated products, but they can alter tablet density, disintegration, and dissolution.

Disintegrant strategy

Croscarmellose sodium is a logical first-line disintegrant because it supports rapid tablet breakup at low concentrations. The formulation should control:

• Intra- versus extra-granular placement
• Disintegrant concentration
• Compression force
• Tablet porosity
• Lubrication time
• Storage humidity

Over-lubrication with magnesium stearate can reduce wetting and slow dissolution. This is especially relevant where velpatasvir dissolution is the critical quality attribute.

Glidant and lubricant strategy

Colloidal silicon dioxide can improve powder flow and reduce content-uniformity risk in a low-dose component system. Velpatasvir represents only one-fifth of the nominal active mass in the reference tablet, so segregation control remains important during blending, transfer, and compression.

Magnesium stearate should be optimized rather than maximized. Alternative lubricants, including sodium stearyl fumarate, can be evaluated where dissolution sensitivity or magnesium-related compatibility is a concern. Any substitution requires comparative dissolution and bioequivalence support.

Film-coating strategy

A conventional polyvinyl alcohol-based coating can provide mechanical protection, swallowability, color identification, and limited moisture protection. Coating weight should be sufficient to protect the tablet without materially delaying disintegration.

Commercial developers can consider:

• Lower-cost aqueous coating systems
• Titanium-dioxide-free coatings for selected markets
• Iron-oxide-based color systems
• Moisture-barrier coatings for tropical distribution
• Opacified coatings that improve stability-indicating appearance control

The opportunity is incremental. Film coating alone is unlikely to create defensible product differentiation unless it solves a demonstrated stability, handling, or patient-use problem.

What are the principal formulation risks?

Velpatasvir dissolution and pH sensitivity

Velpatasvir’s interaction with gastric pH creates the central formulation risk. A generic formulation should demonstrate dissolution across relevant pH conditions, including acidic media and media representing elevated gastric pH. The development package should connect dissolution behavior to pharmacokinetic performance rather than rely only on a single compendial medium.

A formulation that dissolves rapidly in standard acidic medium but loses performance at higher pH may create regulatory and commercial vulnerability.

API-excipient compatibility

Compatibility screening should focus on:

• Moisture-driven degradation
• Oxidative degradation
• Lactose-related reactions
• Peroxide content in polymeric excipients
• Residual solvents
• Light sensitivity
• Solid-state conversion
• Interaction between coating components and APIs

Excipient grades with controlled peroxide, moisture, and particle-size specifications can have higher value than nominally lower-cost grades that generate batch variability.

Content uniformity

Sofosbuvir/velpatasvir combines a relatively high-dose API with a lower-dose API in one tablet. Blend segregation, electrostatic charging, and differences in particle density can produce content-uniformity failures.

Potential controls include ordered mixing, co-sieving, API particle engineering, geometric dilution, dry granulation, or a common granulation step. The preferred process depends on API morphology and stability.

Stability in hot and humid climates

Hepatitis C treatment programs often operate in markets with limited climate control. A commercial excipient strategy should prioritize:

• Low-moisture excipient grades
• High-density HDPE bottles or qualified blister systems
• Desiccant packaging where justified
• Short moisture-exposure times during processing
• Accelerated and long-term stability under ICH and regional conditions

The best opportunity is often a robust, low-cost package rather than a novel excipient.

What formulation patents protect sofosbuvir and velpatasvir products?

The core commercial constraints arise from compound, composition, process, and combination patents associated with Gilead Sciences and related entities. Patent scope has included sofosbuvir, velpatasvir, combinations of antiviral agents, pharmaceutical compositions, and methods of treating hepatitis C.

The U.S. Orange Book is the controlling source for current listed patents and exclusivity information for Epclusa. FDA’s listing should be reviewed by product strength, patent number, expiration date, pediatric extension, and any applicable use code [2].

IP category	Relevance to generic formulation
Sofosbuvir compound patents	May restrict API manufacture or sourcing
Velpatasvir compound patents	May restrict API manufacture or sourcing
Combination patents	May affect the fixed-dose product
Composition patents	May cover excipient architecture or dosage form
Method-of-use patents	May affect labeled treatment populations
Process patents	May create manufacturing freedom-to-operate issues
Packaging or solid-form patents	May affect stability and commercial presentation

An excipient substitution does not automatically avoid a composition patent. A generic company must assess claim language, prosecution history, patent term adjustment, terminal disclaimers, and jurisdiction-specific enforcement.

When does sofosbuvir/velpatasvir lose exclusivity?

Epclusa received U.S. approval on June 28, 2016 [1]. Small-molecule exclusivity and patent exclusivity are separate rights. Regulatory exclusivity can expire before later-expiring patents, and patent expiry can differ across jurisdictions.

The relevant U.S. entry analysis includes:

1. FDA exclusivity for the fixed-dose combination.
2. Orange Book-listed patents.
3. Paragraph IV certification risk.
4. Pediatric exclusivity.
5. Patent-term adjustment or extension.
6. Any settlement-based licensed entry date.
7. Non-U.S. patent and regulatory barriers.

Because commercial entry depends on the complete Orange Book record and current litigation outcomes, a single “loss of exclusivity” date is not a reliable basis for launch planning. Generic applicants must map the ANDA filing date, certification position, litigation stay, and settlement terms against each listed patent [2, 3].

Which companies are challenging or supplying sofosbuvir/velpatasvir?

The competitive landscape has two distinct segments.

U.S. regulated generic market

Potential U.S. competitors include companies that file ANDAs for the fixed-dose combination or obtain rights through settlement arrangements. Entry depends on FDA approval, patent certifications, litigation outcomes, and any agreed launch date.

The principal commercial risk is a clustered launch. Multiple approved ANDAs can compress pricing rapidly, particularly if several suppliers enter near the same date.

Licensed global market

Gilead has supported voluntary licensing and access programs for hepatitis C medicines through arrangements involving the Medicines Patent Pool and qualified generic manufacturers. These programs have expanded access to sofosbuvir-based regimens in numerous lower- and middle-income countries [4].

For licensed manufacturers, the key barriers are often API qualification, technology transfer, quality systems, local registration, pharmacovigilance, and tender performance rather than basic tablet formulation.

What are the commercial opportunities for excipient suppliers?

1. High-volume conventional excipients

The largest near-term opportunity is supplying qualified, cost-competitive grades of:

• Copovidone
• Croscarmellose sodium
• Microcrystalline cellulose
• Lactose monohydrate
• Colloidal silicon dioxide
• Magnesium stearate
• Polyvinyl alcohol coating systems

Suppliers can differentiate through narrow particle-size distribution, low moisture, low peroxide, regional inventory, and regulatory documentation.

2. Excipient systems for dissolution robustness

A prequalified excipient platform that improves wetting and disintegration across pH conditions can reduce formulation-development time. The commercial proposition is stronger if supported by comparative dissolution data, design-of-experiments packages, and scale-up evidence.

3. Tropical-stability platforms

Excipient and coating packages optimized for high temperature and humidity can support public-health tenders. Moisture-resistant coating systems, low-water-activity diluents, and packaging-compatible formulations are more commercially relevant than premium multifunctional excipients with no demonstrated stability benefit.

4. Pediatric and dysphagia-friendly products

Pediatric treatment creates opportunities for:

• Smaller tablets
• Dispersible tablets
• Oral granules
• Taste-masked multiparticulates
• Sprinkle formulations
• Unit-dose sachets

Taste masking is technically important because both APIs can create an unpleasant oral profile. Ion-exchange resins, polymeric coatings, lipid barriers, and multiparticulate systems are possible approaches. The product must preserve dose uniformity and dissolution after dispersion.

5. Low-cost regional manufacturing

A formulation that uses locally available compendial excipients can reduce dependence on imported specialty materials. This is valuable in markets where tender pricing, supply continuity, and local-content requirements determine award decisions.

What is the FDA regulatory status of generic products?

Sofosbuvir/velpatasvir is a small-molecule combination product. Generic applicants generally pursue the ANDA pathway and must demonstrate pharmaceutical equivalence and bioequivalence to the reference listed drug, together with adequate chemistry, manufacturing, and controls documentation [3].

The regulatory package should address:

• Same active ingredients and strengths
• Same route of administration
• Equivalent dosage form
• Comparative dissolution
• Bioequivalence
• Impurity and degradation control
• Manufacturing-process validation
• Stability
• Container-closure qualification
• Labeling consistency

There is no biosimilar pathway for this product. Biosimilar risk is therefore not applicable. The relevant competitive risk is generic substitution, price erosion, and authorized or licensed generic entry.

What patent litigation and Paragraph IV risks affect launch?

A Paragraph IV certification can trigger patent litigation and an automatic stay of FDA approval for up to 30 months, subject to statutory exceptions and litigation developments [3]. A company developing this product should evaluate:

• Whether each Orange Book patent is challenged
• Whether the challenge is based on invalidity, non-infringement, or unenforceability
• Whether the formulation avoids asserted composition claims
• Whether API sourcing creates separate infringement exposure
• Whether a settlement grants an earlier launch date
• Whether the settlement includes supply, license, or volume restrictions

Settlement agreements can create commercial value by allowing an agreed launch before the latest patent expiration. They can also limit the attractiveness of an otherwise technically viable formulation.

How strong is the patent estate for sofosbuvir/velpatasvir?

The estate is stronger at the active-ingredient and combination level than at the level of ordinary excipient selection. A generic formulation using the same broad excipient classes as Epclusa may still avoid infringement if it does not fall within the specific claim limitations. Conversely, replacing one excipient does not create freedom to operate if the patent claims the combination, dosage form, manufacturing process, or treatment method.

The highest-value diligence areas are:

1. Current Orange Book claims.
2. Composition-of-matter expiry.
3. Combination and formulation claims.
4. API supplier patent position.
5. Licensed-market restrictions.
6. Litigation settlements.
7. Country-specific patent status.

What generic launch scenarios exist?

Scenario	Commercial effect
First approved generic	Highest pricing opportunity, subject to litigation and launch rights
Multiple simultaneous entrants	Rapid price erosion and limited formulation differentiation
Licensed-market launch	Volume-led opportunity with lower unit pricing
Pediatric differentiated product	Smaller volume but potentially stronger access positioning
Local tender supplier	Predictable demand if quality and supply continuity are proven
Formulation with non-infringing process	Reduced litigation exposure, but still requires bioequivalence

A conventional tablet is likely to face rapid price competition. The strongest defensible opportunities are supply reliability, pediatric usability, climate robustness, regulatory speed, and access to licensed or public-sector channels.

How does sofosbuvir/velpatasvir compare with competing hepatitis C products?

Product	Formulation and commercial comparison
Epclusa	Pan-genotypic sofosbuvir/velpatasvir tablet; broad generic and access opportunity
Harvoni	Sofosbuvir/ledipasvir; competing NS5A combination with a separate excipient and patent history
Mavyret	Glecaprevir/pibrentasvir; different active ingredients, tablet burden, and competitive patent estate
Vosevi	Sofosbuvir/velpatasvir/voxilaprevir; generally positioned for retreatment and more complex IP
Sovaldi	Sofosbuvir monotherapy; narrower regimen value than the fixed-dose combination

Epclusa has a strong access proposition because it combines pan-genotypic activity with a once-daily tablet. That increases public-health demand but also attracts aggressive generic competition.

Key Takeaways

• Velpatasvir is the main formulation-risk driver because of low solubility and pH-dependent dissolution.
• The reference product uses broadly available excipients, creating a practical generic-development pathway.
• Copovidone, croscarmellose sodium, lactose, microcrystalline cellulose, colloidal silicon dioxide, and magnesium stearate form the core excipient platform.
• Excipient substitutions require comparative dissolution, stability, and bioequivalence justification.
• The best commercial opportunities are generic tablets, pediatric presentations, tropical-stability systems, and licensed-market supply.
• This is a small-molecule generic market, not a biosimilar market.
• Patent risk is concentrated in active ingredients, combinations, compositions, processes, and API supply.
• The current FDA Orange Book and applicable patent litigation records control U.S. launch timing.

FAQs

What is the most important excipient for velpatasvir dissolution?

No single excipient controls performance. The highest-impact variables are the combined disintegrant, binder, lubricant, tablet-porosity, and wetting system. Excessive magnesium stearate or high compression force can reduce dissolution.

Can lactose be replaced in a sofosbuvir/velpatasvir generic?

Yes, but substitution with mannitol, dibasic calcium phosphate, or additional microcrystalline cellulose can change density, hardness, disintegration, and dissolution. The revised formulation requires full comparative development and regulatory support.

Is a softgel formulation commercially attractive for sofosbuvir/velpatasvir?

A softgel could address wetting or solubility concerns but would introduce fill-material, capsule-shell, stability, scale-up, and bioequivalence risks. The conventional tablet remains the lower-risk commercial platform.

Are pediatric oral granules a significant opportunity?

They can be attractive where treatment access includes children aged 3 years and older. The key technical barriers are taste masking, dose uniformity, storage stability, and demonstration that administration with food or soft food does not alter performance.

Can an excipient supplier obtain patent protection for a new sofosbuvir/velpatasvir formulation?

Potentially, if the formulation provides a novel and non-obvious composition, dissolution profile, stability improvement, delivery format, or manufacturing process. Ordinary substitution of one compendial excipient is less likely to support meaningful patent protection.

References

1. U.S. Food and Drug Administration. (2024). Epclusa (sofosbuvir/velpatasvir) prescribing information.
2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
3. U.S. Food and Drug Administration. (2024). ANDA submissions: Amendments and requests for final approval to tentatively approved ANDAs.
4. Medicines Patent Pool. (2017). Hepatitis C licensing and access agreements for sofosbuvir-based treatments.
5. Gilead Sciences, Inc. (2024). Annual report and product information for hepatitis C medicines.